Endometrial Biopsy is Mandatory for Abnormal Endometrial Tissue Observed Grossly
When endometrial tissue appears abnormal to the naked eye during examination, you must obtain histopathologic diagnosis through endometrial sampling—preferably via hysteroscopy with visually directed biopsy rather than blind sampling techniques. This approach provides the highest diagnostic accuracy for detecting endometrial cancer, hyperplasia, and other significant pathology 1, 2.
Diagnostic Approach Algorithm
Step 1: Immediate Tissue Sampling
- Hysteroscopy with directed biopsy is the gold standard for grossly abnormal endometrium, achieving near 100% diagnostic accuracy when combined with tissue sampling 3, 4
- Blind techniques (D&C, Pipelle) should NOT be first-line when malignancy is suspected—they miss up to 10% of endometrial pathology 5
- Office endometrial biopsy has a 10% false-negative rate; if negative in symptomatic patients, proceed to fractional D&C under anesthesia 5, 6
Step 2: Pathology Review by Expert
- All specimens must be reviewed by a specialist gynecologic pathologist 7
- Request immunohistochemistry for p53 and MMR proteins (MLH1, PMS2, MSH2, MSH6) plus POLE hotspot analysis on all specimens regardless of histologic type 8
- This identifies Lynch syndrome patients (5% of endometrial cancers) who require genetic counseling 5
Step 3: Imaging for Staging
- Pelvic MRI is the most accurate preoperative staging modality (98% accuracy for myometrial invasion, 90% for cervical stromal invasion) 7, 8
- Include diffusion-weighted sequences to improve sensitivity/specificity for malignancy 9
- Consider chest imaging and additional CT/PET-CT if high-risk features present 5, 6, 8
Critical Pitfalls to Avoid
Do not rely on endometrial thickness alone. While <4mm in postmenopausal women has nearly 100% negative predictive value for cancer 9, grossly abnormal tissue requires histologic diagnosis regardless of thickness measurements 10, 1.
Do not perform blind sampling as sole diagnostic strategy when focal lesions are visible or suspected. Hysteroscopy detects endometrial polyps and focal cancers that blind techniques miss 11, 1, 2.
Do not skip hysteroscopy in high-risk patients: obesity, diabetes, family history of endometrial/ovarian/breast cancer, tamoxifen use, or Lynch syndrome warrant direct visualization 4, 12.
Age-Specific Considerations
Premenopausal Women
- Endometrial thickness is NOT predictive of pathology in premenopausal women 9
- Biopsy indicated for: abnormal bleeding with risk factors (obesity, PCOS, anovulation), failed medical management, or suspicious imaging 11, 13
Perimenopausal Women (highest AUB incidence)
- Account for 44.5% of AUB cases 12
- Hysteroscopy with directed biopsy mandatory—blind techniques inadequate 4
Postmenopausal Women
- Any endometrial tissue visible or palpable requires sampling 10, 13
- Endometrial thickness >4mm warrants evaluation; >5mm requires biopsy 9
- Tamoxifen users: biopsy if thickness >4mm 2
When Conservative Management Fails
If initial biopsy is negative but symptoms persist or tissue remains grossly abnormal:
- Proceed to fractional D&C under anesthesia 5, 6
- Add hysteroscopy if not previously performed 11, 1
- Consider saline infusion sonohysterography (96-100% sensitivity) to distinguish focal vs. diffuse pathology 11, 9
Evidence Strength Note
The 2026 joint society guideline 1 represents the most recent high-quality evidence, demonstrating hysteroscopy with biopsy provides superior diagnostic accuracy compared to blind sampling for all endometrial pathologies. This supersedes older recommendations favoring blind D&C, though D&C remains appropriate when hysteroscopy is unavailable or after negative office biopsy in symptomatic patients 5.